NCT06471751 Strengthening Inspiratory and Oropharyngeal Muscles in Moderate Obstructive Sleep Apnea Hypopnea Syndrome
| NCT ID | NCT06471751 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Condition | Obstructive Sleep Apnea |
| Study Type | INTERVENTIONAL |
| Enrollment | 38 participants |
| Start Date | 2024-12-30 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 38 participants in total. It began in 2024-12-30 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Obstructive Sleep Apnea hypopnea Syndrome (OSAS), whose prevalence is 4% of the French population, can lead to serious health consequences (risk of road accidents, onset of cardiovascular disease, etc.). OSAS corresponds to a certain number of interruptions (apneas) or reductions (hypopneas) of ventilation during sleep. The weakening of the tone of the inspiratory and oropharyngeal muscles is one of the main causes of upper airways obstruction during the inspiratory phase.
Eligibility Criteria
Inclusion Criteria: * Moderate SAHOS (15 ≤ AHI ≤30); * Body Mass Index (BMI) \< 35 ; * Patient affiliated or entitled to a social security scheme; * Patient having signed a consent to participate in the study. Exclusion Criteria: * Excessive daytime sleepiness: Epworth sleepiness score \> 10 ; * Professional driving and history of accidents related to sleepiness; * Severe obstructive or restrictive ventilatory disorders of neuromuscular origin authenticated by respiratory function tests; * Patients undergoing treatment for OSAS or requiring immediate initiation of continuous positive airway pressure (CPAP) or a mandibular advancement orthosis; * Patients who have stopped CPAP or orthosis treatment in less than one month; * Patients undergoing cardiorespiratory exercise rehabilitation or starting regular physical training; * Uncompensated heart failure, thoracic sternotomy surgery \< 4 months; * Marked osteoporosis with history of rib fractures; * History of spontaneous pneumothorax; * Severe asthma;
Contact & Investigator
Amandine Zellag
PRINCIPAL INVESTIGATOR
Centre Hospitalier Universitaire de Saint Etienne
Frequently Asked Questions
Who can join the NCT06471751 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Obstructive Sleep Apnea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06471751 currently recruiting?
Yes, NCT06471751 is actively recruiting participants. Contact the research team at amandine.zellag@chu-st-etienne.fr for enrollment information.
Where is the NCT06471751 trial being conducted?
This trial is being conducted at Grenoble, France, Saint-Etienne, France.
Who is sponsoring the NCT06471751 clinical trial?
NCT06471751 is sponsored by Centre Hospitalier Universitaire de Saint Etienne. The principal investigator is Amandine Zellag at Centre Hospitalier Universitaire de Saint Etienne. The trial plans to enroll 38 participants.